Loading…

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

Background We studied the efficacy and safety of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy in pediatric patients with autoimmune hepatitis (AIH) who were intolerant or non-responders to standard therapy (corticosteroid and azathioprine). Patients and Methods We performed a re...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2018-05, Vol.63 (5), p.1348-1354
Main Authors: Efe, Cumali, Taii, Haider Al, Ytting, Henriette, Aehling, Niklas, Bhanji, Rahima A., Hagström, Hannes, Purnak, Tugrul, Muratori, Luigi, Werner, Mårten, Muratori, Paolo, Klintman, Daniel, Schiano, Thomas D., Montano-Loza, Aldo J., Berg, Thomas, Larsen, Fin Stolze, Alkhouri, Naim, Ozaslan, Ersan, Heneghan, Michael A., Yoshida, Eric M., Wahlin, Staffan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background We studied the efficacy and safety of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy in pediatric patients with autoimmune hepatitis (AIH) who were intolerant or non-responders to standard therapy (corticosteroid and azathioprine). Patients and Methods We performed a retrospective study of data from 13 centers in Europe, USA, and Canada. Thirty-eight patients (
ISSN:0163-2116
1573-2568
1573-2568
DOI:10.1007/s10620-018-5011-x